Carlyle and SK Capital Partners are buying beleaguered gene therapy biotech Bluebird Bio for about $29 million. Meanwhile, Pfizer continued the culling of its gene therapies with the discontinuation of Beqvez for hemophilia B.
The wet form of age-related macular degeneration (AMD) is currently treated with eye drugs that are blockbuster sellers. Opthea Limited is developing a wet AMD drug that goes after different targets and the biotech struck a pair of financing deals that provide it with the cash for pivotal tests that could show how well its approach works.
Explore top PTSD treatment centers in Arizona, offering personalized care, holistic therapies and expert support to help individuals heal and reclaim their lives.